Trial · NCT03890133
Exploration the Mechanism of Ba-Duan-Jin Therapy in the Management of Fibromyalgia
NCT03890133, Not applicable, Completed, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Exploration the Mechanism of Ba-Duan-Jin Therapy in the Management of Fibromyalgia. Trials, record NCT03890133. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03890133
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploration the Mechanism of Ba-Duan-Jin Therapy in the Management of Fibromyalgia
- NCT number
- NCT03890133
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Conditions
- Fibromyalgia
- Interventions
- Ba-Duan-Jin, Pregabalin capsule
- First posted
- 2019-03-26
- Last updated
- 2024-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change of the Visual Analogue Scale (VAS) for pain from baseline. | Baseline, week4, week8, week12, week24 | Pain VAS, range from 0 to 100 mm with higher score indicating more severe pain. |
| Secondary | Gut microbiota sequencing results by analyzing metagenomes of microbial genes | Baseline, week12 | Fecal samples are obtained from the experimental group and control group. After extracting DNA from fecal samoles, high-throughput Illumina sequencing, gene classification, abundance calculation, functional and metabolic annotation will be performed on the extracted DNA. The Bowtie2, BWA and Soap2 will be selected for the comparison software. The condition of comparison is to obtain the comparison results of 95% identity (and above). |
| Secondary | Serum Brain Derived Neurotrophic Factor (BDNF) levels | Baseline, week12 | Serum BDNF levels were measured in healthy control group and FM patients |
| Secondary | The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline. | Baseline, week 4, week 8, and week 12. | A self-administered questionnaire with 10 subscales, measuring fibromyalgia symptoms and function domains. FIQR total score ranges from 0 to 100, with higher scores indicating more severe symptoms |
| Secondary | Global Impression of Change (PGIC) questionnaire evaluated at week 12. | Week 12. | A questionnaire determine any change in overall symptom status from the beginning of the study to its conclusion (score range, 1 \[very much improved\] to 7 \[very much worse). |
| Secondary | fMRI of the brain in patients with fibromyalgia | Baseline, week12 | To compare the changes in structure, connectivity and metabolic function of the brain in patients with fibromyalgia before and after treatment by fMRI. |
| Secondary | Serum Tyrosine kinase B (TrkB) levels | Baseline, week12 | Serum TrkB levels were measured in healthy control group and FM patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03890133
GET https://conductscience.org/api/trials/v1/NCT03890133/registered